Table 1.
Clinicopathological characteristics of recurrent gastric cancer patients
| Early recurrence (n = 248) n (%) | Late recurrence (n = 154) n (%) | Pvalue | |
|---|---|---|---|
| Age, years | 0.392 | ||
| <65 | 109 | 61 | |
| ≥65 | 139 | 93 | |
| Gender, male/female | 162/86 | 100/54 | 0.937 |
| Tumor size, cm | 0.013 | ||
| <5 | 76 | 68 | |
| ≥5 | 172 | 86 | |
| Gastrectomy | 0.061 | ||
| Total | 91 | 71 | |
| Subtotal | 157 | 83 | |
| Location | 0.232 | ||
| Upper | 46 | 27 | |
| Middle | 49 | 20 | |
| Lower | 130 | 95 | |
| Diffuse | 23 | 12 | |
| Gross appearance | 0.001 | ||
| Superficial tumor | 18 | 25 | |
| Bormann type I and II | 25 | 40 | |
| Bormann type III and IV | 205 | 89 | |
| Histology type | 0.315 | ||
| Differentiated | 76 | 40 | |
| Undifferentiated | 172 | 114 | |
| Lauren’s classification | 0.572 | ||
| Intestinal type | 104 | 69 | |
| Diffuse type | 144 | 85 | |
| Lymph node metastasis | 0.002 | ||
| Negative | 52 | 54 | |
| Positive | 196 | 100 | |
| Lymphovascular invasion | 0.003 | ||
| Absent | 57 | 56 | |
| Present | 191 | 96 | |
| Depth of invasion | <0.001 | ||
| T1 and T2 | 46 | 53 | |
| T3 and T4 | 202 | 101 | |
| TNM stage | <0.001 | ||
| I | 14 | 27 | |
| II | 43 | 59 | |
| III | 191 | 68 | |
| Lymph node dissection | 0.414 | ||
| D1 | 109 | 75 | |
| D2 | 86 | 54 | |
| D3 | 53 | 25 | |
| EMT expression (%) | |||
| Aberrant expression of mesenchymal marker | |||
| Snail-1 | 117(47.2) | 64(41.6) | 0.271 |
| ZEB-1 | 168(67.7) | 109(70.8) | 0.522 |
| Vimentin | 87(35.1) | 21(13.6) | <0.001 |
| Expression loss of epithelial marker | |||
| E-cadherin | 112(45.2) | 35 (22.7) | <0.001 |
| β-catenin | 29 (11.7) | 19(12.3) | 0.846 |
| Expression of cancer stem cell marker (%) | |||
| CD44 | 163(65.7) | 71(46.1) | 0.001 |
| CD54 | 120(48.3) | 63(40.9) | 0.037 |
| Adjuvant chemotherapy, yes/no | 221/27 | 142/12 | 0.308 |